Periodontitis is fundamentally a dysbiotic disease: the shift from a balanced subgingival microbiome toward a pathogen-dominated community drives the destructive host response that defines the condition. Controlling this dysbiosis — not merely reducing pocket depth — is increasingly recognized as the true target of supportive periodontal therapy. This randomized triple-blind clinical trial investigated whether the adjunctive use of probiotics and ozonated olive oil, administered during the maintenance phase, could help preserve or restore oral eubiosis in patients diagnosed with Stage I and II periodontitis.

The study enrolled patients already treated for Stage I or II periodontitis and randomized them into experimental and control arms. The experimental group received a combination of oral probiotics — selected strains with documented activity against periodontal pathogens — alongside ozonated olive oil, a compound with broad-spectrum antimicrobial and anti-inflammatory properties attributable to its ozone-derived reactive oxygen species. The control group received placebo equivalents. The triple-blind design minimized performance and detection bias across patients, clinicians, and outcome assessors. Clinical parameters — including probing pocket depth, bleeding on probing, and plaque index — were recorded alongside microbiological assessments to evaluate shifts in the composition of the subgingival and supragingival microbiota over the observation period.

The results indicated that the probiotic and ozonated olive oil combination supported a more stable microbial equilibrium compared to placebo, with measurable reductions in the prevalence of recognized periodontal pathogens and favorable trends in clinical inflammatory markers. Bleeding on probing and pocket depth showed improvement or stabilization in the experimental group relative to controls, suggesting that the adjunctive regimen contributes to maintaining the clinical gains achieved through active periodontal therapy.

The clinical relevance of these findings is concrete. Maintenance is where periodontal treatment most frequently fails — not because of inadequate initial therapy, but because dysbiosis tends to re-establish itself in susceptible patients without targeted ecological intervention. A non-antibiotic adjunctive strategy capable of sustaining eubiosis addresses precisely this vulnerability. Probiotics work by competitive exclusion, production of bacteriocins, and modulation of the host immune response; ozonated olive oil adds a direct antimicrobial action with minimal risk of resistance induction. Together, they represent a biologically rational, pharmacologically conservative option to integrate into maintenance protocols.

For the periodontist, the take-home message is straightforward: in Stage I and II patients, where the therapeutic window allows for conservative management, adjunctive probiotics combined with ozonated olive oil may reduce the rate of microbiological and clinical relapse between maintenance visits. This does not replace meticulous professional debridement or patient-performed oral hygiene, but it adds an active ecological layer to the maintenance strategy — one that is well-tolerated, low-risk, and aligned with the current understanding of periodontitis as a dysbiotic, polymicrobial condition.